Cyrus Biotechnology signs protein-engineering deal with Selecta Biosciences worth up to $1.5 billion to develop IL-2/ImmTOR immune therapy

Seattle-based Cyrus Biotechnology struck a protein-engineering collaboration with Boston’s Selecta Biosciences to engineer IL-2 combined with Selecta’s ImmTOR, a deal that could pay Cyrus up to $1.5 billion if milestones are met. Cyrus will use its software and lab testing to enhance IL-2 stability and function, adding to its existing partnerships and commercial sales of Cyrus Bench.

CCyrus Biotechnology UUniversity of Washington